



Webinar | IMI2 – Call 20 Rules and procedures

29.01.2020

Agenda

- How to use GoToWebinar – Catherine Brett, IMI
- IMI rules and procedures – Nathalie Seigneuret, Fabrizio Federici, Desmond Barry, IMI
- Questions & answers

How to use GoToWebinar

Expand / minimise control panel →

Microphone status →

Full screen →

Raise / lower your hand
e.g. if you want to ask a
question orally

Send a question in writing →

The screenshot shows the GoToWebinar interface with several key elements highlighted by a red border and green arrows:

- Expand / minimise control panel:** A green arrow points to a red circle around the right-pointing arrow icon in the top-left corner of the control panel.
- Microphone status:** A green arrow points to the microphone icon in the top-left corner of the control panel.
- Full screen:** A green arrow points to the full-screen icon in the top-left corner of the control panel.
- Raise / lower your hand:** A green arrow points to the hand icon in the top-left corner of the control panel.
- Send a question in writing:** A green arrow points to the text input field in the Questions section.

The interface includes the following components:

- Audio Control Panel:** Features a menu (File, View, Help), a Sound Check indicator, and options for Computer audio (selected) and Phone call. The microphone is currently MUTED. Output devices are set to Transmit (Plantronics Savi 7xx-M) and Receive (Plantronics Savi 7xx-M).
- Questions Section:** A section titled "Questions" with a text input field containing "[Enter a question for staff]" and a "Send" button.
- Webinar Housekeeping:** Displays "Webinar ID: 608-865-371" and the GoToWebinar logo.

How to use GoToWebinar - audio

To listen via your computer, select **Computer audio**


Can't hear us?

- Check your **speakers are switched on and not muted**
- Do a **Sound Check** to make sure GoToWebinar is picking up the right speakers
- Still not working? Select **Phone call** and dial the numbers given on your phone

To listen in via your phone, select **Phone call**, pick your country, and dial the numbers given

Can't hear us?

- Check you have selected **Phone call** in the audio panel
- Try **another country's** phone number
- Still not working? Select **Computer audio** and listen over your computer's speakers



Before we start...

- This webinar is being recorded and will be published on the IMI website and / or IMI YouTube channel
- Presentation slides will be published on the webinar web page
- A participant list will be published on the website
- IMI2 – Call 20 has been launched and all Call documents & details of how to apply can be found on the IMI website



Rules and procedures for IMI2 Calls for proposals


Outline

1. Introducing IMI
2. Participation rules
3. Funding rules
4. Intellectual property rules
5. From Call to grant award
6. Writing a successful proposal
7. More information



Introducing IMI

Challenges in medicines development



IMI – key concepts

- Non-competitive collaborative research
- Competitive Calls for proposals
- Open collaboration in public-private consortia
 - Data sharing, dissemination of results...
- Industry contribution is in kind



IMI2 budget (2014 – 2020)

EU funding goes to:

Universities
SMEs
Mid-sized companies
Patient groups
etc...



€1.638 bn



€1.425 bn

Other
€213 m

IMI 2 total budget
€3.276 billion

EFPIA companies

receive no funding
contribute to projects 'in kind'

Associated Partners e.g. charities, non-EFPIA companies

IMI2 Strategic Research Agenda

- Antimicrobial resistance
- Osteoarthritis
- Cardiovascular diseases
- Diabetes
- Neurodegenerative diseases
- Psychiatric diseases
- Respiratory diseases
- Immune-mediated diseases
- Ageing-associated diseases
- Cancer
- Rare/Orphan Diseases
- Vaccines



The right prevention and treatment
for the right patient at the right time

Strategic Research Agenda for
Innovative Medicines Initiative 2

**Aligned with
WHO priorities**

IMI life cycle

- **Call topics definition**
 - Scientific Research Agenda
 - Strategic Governing Groups
 - Annual Work Plan
 - Consultation Member-Associated States/Scientific Committee
- **Call Launch / Evaluation / Grant award**
- **Project implementation**

Consortium agreement, Grant agreement, implementation and reporting

What does the typical IMI project look like?

Industrial partners align themselves around a real challenge for industry and agree to work together and commit resources


New ideas from public sector, universities, SMEs etc. are needed to address the challenge

Scale is a key to success and is provided by IMI funding and the outcomes should be transformative for the industry as well as having a clear “public” value

A typical IMI consortium



An international, cross-sector community



Why applying to IMI Call for proposals?

- Allow engagement in a cross-sector, multi-disciplinary consortium at the forefront of cutting-edge research
- Provide the necessary scale by combining funding, expertise, knowledge, skills and resources
- Build a trustful collaboration based on creativity and innovative and critical thinking
- Learn from each other - new knowledge, skills, ways of working
- Take part in transformative research that will make a difference in drug development and ultimately patients' lives

IMI - ecosystem for innovative collaborations on **shared challenges.**



Introduction to IMI2 JU – Call 20

IMI2 JU Call 20 - topics

- **Topic 1: Early diagnosis, prediction of radiographic outcomes and development of rational, personalised treatment strategies to improve long-term outcomes in psoriatic arthritis**
- **Topic 2: Innovations to accelerate vaccine development and manufacture**
- **Topic 3: Academia and industry united innovation and treatment for tuberculosis (UNITE4TB)**
- **Topic 4: Tumour plasticity**
- **Topic 5: Proton versus photon therapy for oesophageal cancer – a trimodality strategy**
- **Topic 6: Handling of protein drug products and stability concerns**

IMI 2 JU - Call 20 two stages

- Date of Call launch: 21 January 2020
- Calls text and documents are published on the:
IMI2 JU website and the Funding and Tenders Portal
- **Deadline for Short Proposal submission:** 21 April 2020
(17:00:00 Brussels time)
- **Deadline for Full Proposal submission:** 5 November 2020
(17:00:00 Brussels time)
- Webinar topic presentations and recordings will be available from the IMI website.

Call 20 – two stages

- At stage 1 evaluation the **budget** is evaluated under criterion 3 'Quality and Efficiency of the Implementation'
- Applicants will need to provide a breakdown of costs (and not only the overall amount, as previously the case), by filling in the budget table in Part A of the proposal

Budget for the proposal

Participant	Country	(A) Direct personnel costs/€	(B) Other direct costs/€	(C) Direct costs of sub- contracting/€	(D) Direct costs of providing financial support to third parties/€	(E) Costs of inkind contributions not used on the beneficiary's premises/€	(F) Indirect Costs / € (=0.25(A+B-E))	(G) Special unit costs covering direct & indirect costs / €	(H) Total estimated eligible costs / € (=A+B+C+D+F +G)	(I) Reimburse- ment rate (%)	(J) Max.EU Contribution / € (=H*I)	(K) Requested EU Contribution/ €
		?	?	?	?	?	?	?	?	?	?	?
		0	0	0	0	0	0,00	0	0,00	100	0,00	0,00
Total		0	0	0	0	0	0,00	0	0,00		0,00	0,00

Call 20

Applicants must use the electronic submission service which is under the **Funding and Tenders Portal**:

<https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/home>

- To access the portal and submit a proposal, applicants must have:
 - An **EU Login account** (previously, 'ECAS' account)
 - Their **organisation registered** on the Participant Portal Beneficiary Register, with a 9-digit **Participant Identification Code (PIC) number**

If you do not have an EU Login account yet, you can create an EU Login account on the Funding and Tenders Portal , and register your organisation.

More information: http://ec.europa.eu/research/participants/docs/h2020-funding-guide/user-account-and-roles/ecas-login_en.htm



Participation rules

A single set of rules



EU Financial
Regulation
Specific rules
for
participation

- Covering all H2020 research and innovation actions
- Adaptability where needed:
 - Entities eligible for funding
 - IP

Conditions for Call 20 two-stages

H2020 Rules for participation apply to IMI2 JU Call for Proposals and Actions except where specifically derogated

- **Minimum conditions**

RIA: at least three independent legal entities, each established in a different EU Member State or H2020 associated country

- **Two-stages - C20**

Stage 1 SPs from applicants requesting JU funding

Stage 2 merging 1stranked SPs with industry consortia

- **Evaluation criteria**

At stage 1, all 3 criteria are evaluated (including budget)

Evaluation criteria, thresholds and Proposal templates have been revised as of Call 18

- Threshold is 3 for each of the evaluation criteria 'excellence', 'impact' and 'quality and efficiency of the implementation'
- the overall threshold is 10

Conditions for Call 20 two-stages

- **Submission tool**

SPs/FPs to be submitted through the Electronic Submission Service under the Funding and Tenders Portal

- **Submission deadlines**

Established in the Call topic text both for stage 1 and 2

- **Indicative contribution**

For each topic, the maximum JU contribution and the estimated industry contributions are set in the call text

- **Hearings**

Panels may decide at stage 1 to hold hearings with applicants during panel meetings. After submission deadline, coordinators will be informed about the possible date for the hearing (👉 **check SP details!**)

Conditions for Call 20 two-stages

- **Information on the outcome of the evaluation:**

Information to the applicants - max 5 months from submission deadline

N.B. GA signature is expected by April 2021, specific timelines will be provided after stage 2.

- **Financial Support to Third Parties**

Where relevant, applicants should develop in FPs open, transparent, objective processes and criteria for the allocation of financial support in accordance to Annex K of the H2020 WP and article 15 of the IMI2 JU MGA

- **Plan for exploitation and dissemination**

It must be included in 2nd stage Full proposals

NB: Contacts/discussions about a given topic between potential applicant consortia and members of the industry consortium are prohibited throughout the procedure until the results of the first stage evaluation.

Attracting stakeholders

Any legal entity, regardless its place of establishment, carrying out work relevant to the Call objectives may be part of applicant consortia

But... not all participating entities are eligible for funding

Who is eligible for funding?

- Academic institutions
- Small & medium-sized enterprises (SMEs)
- Mid-sized enterprises (\leq €500m)
- Non-profit organisations e.g. research organisations, patient organisations, NGOs, public bodies, intergovernmental organisations etc.

Established in:

- **EU Member State**
- **Associated Country**

Other countries:

No funding unless participation deemed essential by IMI2 JU for carrying out the action

Art.1 Commission Delegated Regulation (EU) No 622/2014

Expected consortia – Call 20

Stage 1 of two stage - Short Proposals

- **Consortia consisting of:**
 - IMI2 JU fundable legal entities carrying out activities relevant for achieving the project objectives
 - additional legal entities carrying out activities relevant for achieving the project objectives.

Expected consortia Call 20

Stage 2 of two stage – Full Proposals

- **One Full Consortium per topic consisting of:**
 - 1st ranked SP consortium - IMI2 JU fundable legal entities/additional legal entities
 - ☞ Under Topic 2 - 1st ranked consortium selected under each (of 4) sub-topic are merged
 - Industry consortium (EFPIA companies and IMI2 JU Associated Partners) associated to the relevant topics



Funding rules

IMI2 JU Funding model

- **IMI2 JU is a PPP, actions are normally co-funded by:**
 - JU funding to BRFs (**b**eneficiaries receiving funding = legal entities eligible for funding)
 - In-kind/cash contribution from BNRFs (**b**eneficiaries **not** receiving funding):
 - EFPIA constituents and affiliates
 - IMI2 JU Associated Partner
 - (future other IMI2 members)

Other legal entities may also participate as BNRFs at their own cost

One single funding rate per project - BRFs

One project = One rate

For all beneficiaries and all activities

- 100% of the direct eligible costs
- Indirect costs: **25% flat rate**

JU contribution to BRFs covers:

- **Personnel**

- Wider acceptance of average personnel costs
- Acceptance of supplementary payments
For non-profit organisations of up to 8000 euros/year/person
- Less requirements for time records

- **Equipment, consumables, travels...**

- **Subcontracting**

Considering BRFs accounting and management principles

- **BRFs (only) may also receive Financial contribution from EFPIA/APs**

- to be reported as receipts

IMI2 JU GA: third parties

Third party is a *legal entity which carries out work of the action, supplies goods or provide services for the action, but which did not sign the grant agreement*

Types of third parties:

1. Third parties directly carrying out part of the work described in Annex 1 of the GA
2. Other third parties: providing resources, goods or services to beneficiaries carrying out the work described in Annex 1
3. Third parties receiving financial support (money) from the beneficiary as part of the action, subject to specific conditions, i.e. Annex K H2020 WP

Overview different types of third parties in GA

TYPE	CHARACTERISTICS						
	Works on action tasks?	Provides resources or services for action?	What is eligible?	Must be indicated in Annex 1?	Indirect costs?	Selecting the third party	GA articles
Linked third party	YES	NO	Costs	YES	YES	Must be affiliated or have a legal link and be eligible for funding	Article 14
International partners	YES	NO	N/A	YES	N/A	Must not be eligible for funding	Article 14a
Subcontractor	YES	NO	Price	YES	NO	Must be best value for money, avoid conflict of interest	Article 13
Third party providing in-kind contribution	NO	YES	Costs	YES	YES	May not be used to circumvent the rules	Articles 11 and 12
Contractor (selling, equipment, good or service)	NO	YES	Price	NO	YES	Must be best value for money, avoid conflict of interest	Article 10
Third parties receiving financial support ³¹	The third parties participate in the action as recipients.		Amount of support given	YES	NO	According to the conditions in Annex 1	Article 15

EFPIA and Associated Partners contribution - BNRFs

- EFPIA companies
- Other industries and partners (= Associated Partners to IMI2)
 - In-kind (actual direct and indirect costs or average FTE) and/or financial contributions (FC)*
 - Based on the usual management principles and accounting practices
 - Contributions from affiliated entities as part of in-kind

* Recipient of FC must be BRFs, i.e. eligible for JU funding

When relevant to IMI2 JU objectives: non-EU in-kind contribution (up to 30% at programme level)

Annual financial reporting is disconnected from GA periodic reports

Deadlines for reporting

- Scientific reporting (full consortium) due at project deadlines (i.e.GA), duration reporting period: 12 months
- Financial reporting for:
 - Beneficiaries receiving JU funding, due at project deadlines (i.e.GA)
 - CFS: >EUR 325k at project end
 - Beneficiaries Not receiving funding (e.g. EFPIA companies and APs),
 - due by 31 Jan - certification by 30 April - covering previous calendar year


IMI2 JU's Intellectual Property (IP) rules

One set of rules for multiple interests

Support to
industry

Incentive to
participate


Freedom of
access



Dissemination
of information

Compensation
for IP

Background vs. Results



Ownership of results

Results are owned by the beneficiary that generates them

Possible transfer of ownership of Results only after their generation:

- Pre-allocation of ownership **NO**
- Prior agreement on transfer after generation **YES**

Protection of results

Mandatory for beneficiaries receiving funding

- lies with the owner(s) in adequate and effective manner based on relevant (national) legal provisions, action peculiarities, type of result and legitimate interests
- Type of protection to be reported to the JU
- if valuable results left unprotected, to be discussed within the consortium and inform JU

Access Rights

Articles 25 IMI2 MGA (to background) and 31 IMI2 MGA (to results)

- Access rights = rights to use
- Mandatory written request
- Access rights are in principle not sub licensable but beneficiaries may agree in the consortium agreement to define certain situations where sublicense apply => **Traceability**
- Time limit to request access rights
 - No minimum/maximum
 - Consistent with particular project/results/background

Mandatory access rights: right to use

Background

- Access rights to beneficiaries
- for action implementation (including to affiliated entities)
 - If needed for research use of results

Results

- Access rights to beneficiaries:
- for action implementation (including to affiliated entities)
 - For research use of results

Background

- Access rights to third parties:
- after completion of the action
 - if needed for research use of results
 - possibility to exclude certain elements

Results

- Access rights to third parties:
- after completion of the action
 - within established time limits
 - for research use of results

Purposes of Access Rights: Research Use vs. Direct Exploitation

Research Use

- Use of results or background necessary to use the results for all purposes other than for completing the action or for direct exploitation
- The application of results (like an animal model or a biomarker) as a tool for research and clinical research in the discovery or development (as the case may be for commercialisation) of pharmaceutical products by for-profit institutions and organisations

Direct Exploitation

- Development for commercialisation or to commercialise the results
- Commercialisation of such biomarker itself as a diagnostic kit would be direct exploitation

Access Rights conditions

Access rights granted by a beneficiary to/on	Background (necessary and identified)	Results	Sideground
Beneficiaries for completion of the action	Royalty-free	Royalty-free	N.A.
Beneficiaries and affiliates for Research Use	Fair & reasonable conditions (e.g. Royalty-free conditions)	Fair & reasonable conditions (e.g. Royalty-free conditions)	N.A.
Third Parties for Research Use after the action	Appropriate conditions	Appropriate conditions	N.A.
Beneficiaries and affiliates or Third Parties for Direct Exploitation	To be negotiated	To be negotiated	N.A.

Dissemination modalities

Each beneficiary has the obligation to disseminate its own results

As soon as reasonably practicable

For publications: Open access is mandatory

Mandatory to mention IMI support & EFPIA in-kind contribution in patent applications / all communications & dissemination

IMI2 JU Communication guide:

<https://www.imi.europa.eu/apply-funding/call-documents/imi2-call-documents>

Open Access in IMI2 JU Projects

Open Access to Publications

(Article 29.2 GA)

Deposit in repositories and publishing in Open Access (OA).

OA charges may be considered eligible costs.

Open Research Data (ORD)

(Article 29.3 GA)

IMI2 projects are part of the ORD:

- 'underlying data to published results' generated in the project, and any other data.

'As open as possible as closed as necessary': balance between openness and protection of scientific information and IPR

Data Management Plan (DMP)

(AWP)

All projects need to develop and update a DMP, even if opted out from the ORD.

DMPs should aim to produce 'FAIR' data:

Findable

Accessible

Interoperable

Re-usable

Reference documents


- **H2020 Rules for Participation**
 - IPR section: Article 1.3.c and Articles 41 to 49
- **IMI2 – EC Delegated Regulation**
 - IPR section: Articles 2 to 7
- **IMI2 model Grant Agreement** (revised November 2017)
 - IPR section: Articles 23a to 31
- **IMI2 annotated Grant Agreement**

www.imi.europa.eu/apply-funding/call-documents/imi2-call-documents




From Call to grant award

IMI2 JU Call 20 two-stages



A single set of evaluation criteria



- As of Call 18, the evaluation criteria, thresholds and proposal templates have been revised
- Two-stage evaluation: all three criteria considered at both stages
- Thresholds and weighting in the **Call documents** depending two-stages/single stage
- Minimum of **3 independent experts**

Each proposal **evaluated 'as it is'**, not as 'what could be'

Keeping the momentum

Maximum Time To Grant: 8 months from submission of full proposal:

N.B. Call 20 GAs expected to be signed by April 2021

5 months
for informing applicants
of scientific evaluation

3 months
for signature of grant
agreement

NEW Legal entity validated in parallel

IMI2 Grant Agreement



- The new IMI2 JU MGA (v.5) will apply to Call 20
- It follows H2020 Model Grant Agreement (v.5) with IMI2 specificities.
- IMI2 JU Annotated Model Grant Agreement v.2.2 (based upon H2020 AGA v.5.2)
- It is e-signed between IMI2 JU and Coordinator only. Other beneficiaries e-sign Accession Forms
- EFPIA and Associated Partners are beneficiaries not receiving funding (BNRFs, Art.9) - their financial report occurs outside the GA, for more info please consult '*IMI2 JU guidelines for reporting in kind and financial contributions by Members other than the Union and Associated Partners*'

IMI2 Grant Agreement

Article 41.3 - Consortium agreement *may cover*:

- *internal organisation of the consortium, including allocation of scientific tasks among beneficiaries*



Scientific Project Leadership

Scientific Project Leader may be different from Coordinator to:

- reflect the spirit of industrial co-leadership in call topics built upon EFPIA/industry scientific priorities
- address the need for strong scientific coordination and collaboration between BRFs (JU funded) and BNRFs (industry)



IMI2 specificities are presented in the IMI2 JU AGA

Consortium agreement

- Contractual arrangement **between all participants** to set out their rights and obligations, especially governance, liability and IPR
- Shall comply with the **IMI2 JU Model Grant Agreement**
- To be agreed before the signature of the GA, IMI2 JU is not a party
- **To be adapted to the specific needs of each IMI action!**
- A template prepared by EFPIA shows what a consortium agreement might look like:

<http://efpia.eu/documents/229/141/EFPIA-Consortium-Agreement-Template-for-IMI2-actions>

Consortia may also use alternative templates if they wish.



Tips for success

Common Mistakes

- **Admissibility/Eligibility criteria not met:**
 - Submission **deadline** missed
 - Proposal **out of scope**
(if you have doubts on how to respond to the Call contact us)
 - Not involving at least **three independent legal entities** (RIA) from **three** different **MS/AC**

Common Mistakes

- The proposal does not address all the **objectives** (in some cases proposals have nothing to do with the topic!)
- Submitted text does not respect the proposal template (sometimes received even slides!)
- Ensure to follow the instructions of the proposal template
- Applicants do not have the **capabilities** to address all of the objectives or there is redundancy between partners
- A proposal is scientifically excellent but will have **limited impact**
- **Budget**, either over-estimated or not fully justified
- **Ethical issues** not addressed

Tips

- **Read all the Call-relevant material that is provided on the IMI website – www.imi.europa.eu**
- **Understand IMI2 JU rules** and respect them
- **Consider the PPP dimension** of the action (e.g. Governance, industry contribution vs IMI2 JU funding)
- **If in doubt, ask** a member of the Programme Office
- Your proposal should provide **reviewers** with all the information requested to allow them to evaluate it
- Start **working early** (pre-materials available before)
- Dedicate sufficient time to submit the proposal: create an EU login account, obtain a PIC number - **don't wait until the last day to start the submission process**
- **More tips:** www.imi.europa.eu/content/tips-applicants

Submitting a proposal

Via the **new** Funding and Tenders Portal

<https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/home>

The screenshot shows the 'Funding & tender opportunities' portal. At the top, there is a header with the European Commission logo and the text 'Funding & tender opportunities Single Electronic Data Interchange Area (SEDIA)'. On the right, there are links for 'English EN', 'Register', and 'Login'. Below the header is a navigation bar with a home icon and menu items: 'SEARCH FUNDING & TENDERS', 'HOW TO PARTICIPATE', 'PROJECTS & RESULTS', 'WORK AS AN EXPERT', and 'SUPPORT'. A 'select programme' button is also present.

The main content area features a blue banner with the text: 'The Funding & Tenders Portal is the entry point (the Single Electronic Data Interchange Area) for participants and experts in funding programmes and tenders managed by the European Commission and other EU bodies.' A 'Feedback' button is on the right.

Below the banner is a section titled 'Find calls for proposals and tenders' with a search bar containing the placeholder text 'Search calls for proposals and tenders by keywords, programmes...' and a yellow 'Search' button.

The bottom section is titled 'Calls for proposals by EU Programme' and contains a grid of 14 programmes. The 'Horizon 2020 Framework Programme (H2020)' is circled in red.

3rd Health Programme (3HP)	Asylum, Migration and Integration Fund (AMIF)	Consumer Programme (CP)	Creative Europe (CREA)	Erasmus+ Programme (EPLUS)	European Maritime and Fisheries Fund (EMFF)	HERCULE III (HERC)	Horizon 2020 Framework Programme (H2020)
Internal Security Fund Borders and Visa (ISFB)	Internal Security Fund Police (ISFP)	Justice Programme (JUST)	Pilot Projects and Preparatory Actions (PPPA)	Programme for the Competitiveness of	Promotion of Agricultural Products (AGRIP)	Research Fund for Coal & Steel (RFCS)	Rights, Equality and Citizenship Programme

Submitting a proposal

Look for IMI2 JU Calls, you will find the links to start the submission of a proposal:

The screenshot displays the European Commission's 'Funding & tender opportunities' portal. The search results are filtered for 'IMI2' grants. The results list three grants, each with details on the types of action, opening dates, and deadlines.

Search Results:

- Grant: Optimising future obesity treatment IMI2-2019-17-01**
Types of action: Research and Innovation action | Programme: Horizon 2020
Open for submission: 22 January 2019
Deadline model: two-stage
Deadline date: 25 April 2019 17:00:00 Brussels time
Second stage deadline: [dropdown]
- Grant: Open access chemogenomics library and chemical probes for the druggable genome IMI2-2019-17-02**
Types of action: Research and Innovation action | Programme: Horizon 2020
Open for submission: 22 January 2019
Deadline model: two-stage
Deadline date: 25 April 2019 17:00:00 Brussels time
Second stage deadline: [dropdown]
- Grant: Intelligent prediction and identification of environmental risks posed by human medicinal products IMI2-2019-17-03**
Types of action: Research and Innovation action | Programme: Horizon 2020
Open for submission: 22 January 2019
Deadline model: two-stage
Deadline date: 25 April 2019 17:00:00 Brussels time
Second stage deadline: [dropdown]

Proposal Submission Form - Part A

Please indicate only one of the following options if applicable to your organisation

Companies (including micro enterprises and SMEs) with an annual turnover up to EUR 500 millions which are not affiliated entities of companies with an annual turnover of more than EUR 500 millions

Patients Organisation

Regulatory Agency

Member of EFPIA not requesting funding

IMI2 Associated Partners to this topic not requesting funding

Any other organisation not requesting funding

Certain type of organisations are not covered by the above options, in that case none should be selected

- Where applicable, the organisation type has to be indicated (see above):
 - Applies to the 6 types of organisations identified in the form;
 - If none of the options is selected, the system generates a warning;
 - The warning is not blocking the submission of the proposal.

Proposal Submission Form - Part A

Validation result

Show Error The red 'Show Error' button indicates an error due to a missing or incorrect value related to the call eligibility criteria. The submission of the proposal **will be blocked** unless that specific field is corrected!

Show Warning The yellow 'Show Warning' button indicates a warning due to a missing or incorrect value related to the call eligibility criteria. The submission of the proposal **will not be blocked** (proposal will be submitted with the missing or incorrect value).

Section	Description	
Legal Entity	Please indicate if your organisation is one of the following legal entity.	Show Warning
Legal Entity	Please indicate if your organisation is one of the following legal entity.	Show Warning
Legal Entity	Please indicate if your organisation is one of the following legal entity.	Show Warning
Legal Entity	Please indicate if your organisation is one of the following legal entity.	Show Warning
Legal Entity	Please indicate if your organisation is one of the following legal entity.	Show Warning
Legal Entity	Please indicate if your organisation is one of the following legal entity.	Show Warning
Legal Entity	Please indicate if your organisation is one of the following legal entity.	Show Warning
Legal Entity	Please indicate if your organisation is one of the following legal entity.	Show Warning
Budget	The indirect cost (F) for the project is zero. Please check the budget columns (A),(B) and (E).	Show Warning
Budget	The requested EU Contribution (K) value cannot be zero.	Show Warning

- When validating the forms, different warnings appear (see above):
 - The yellow warnings don't block the submission of the proposal;
 - Only the warnings flagged in red will block the submission of the proposal.

Proposal Submission Form - Part A

4 - Call specific questions

Essential information to be provided for proposals including clinical Trials / studies / investigations

Applies to proposals including clinical trials / studies / investigations

Are clinical studies / trials / investigations included in the work plan of this project?	<input checked="" type="radio"/> Yes	<input type="radio"/> No
---	--------------------------------------	--------------------------

Please upload the dedicated annex 'Essential information for clinical studies / trials / investigations' (a Word template is provided under 'download templates' in the up-load section for Part B and Annexes).

This document should include the relevant information of each clinical study / trial / investigation included in the work plan of this project.

Please give a short title, an acronym or a unique identifier to each clinical study / trial / investigation, <u>to be used as a reference/ identifier in the other parts of the proposal.</u>	
<i>Give short title/acronym/unique identifier</i>	

- If the proposal includes clinical trials/studies/investigations, in stage one of two-stages calls, the specific annex is not requested (see above the section):
 - In stage one relevant aspects should be integrated in part B of the proposal template;
 - The dedicated annex is compulsory in stage two (see *Clinical trial template*).



More information

Stay in touch

- Visit our new website www.imi.europa.eu
- Sign up to our newsletter [via the website](#)
- Follow us on Twitter [@IMI_JU](https://twitter.com/IMI_JU)
- Join our LinkedIn group bit.ly/LinkedInIMI
- E-mail us infodesk@imi.europa.eu



The screenshot shows the IMI website homepage. At the top left is the IMI logo and the text 'innovative medicines initiative'. To the right is the tagline 'Europe's partnership for health'. Below this is a navigation bar with links: Home, About IMI, Get involved, Apply for funding, Projects & results, News & events, and Reference documents. The main content area features a large image of a petri dish with colorful bacterial colonies. A text box overlaid on the image reads: 'We are an EU public-private partnership funding health research and innovation'. At the bottom, a statistics bar displays: €5.3bn BUDGET, 90 PROJECTS, 864 PARTICIPANTS, 6 995 PROJECT OUTPUTS, and 2 686 PUBLICATIONS.

The screenshot shows the IMI Twitter profile page. The profile name is 'IMI' (@IMI_JU) with a bio: 'The Innovative Medicines Initiative (IMI) is a public-private partnership aiming to speed up the development of better and safer medicines for patients.' It lists the location as Brussels, the website as imi.europa.eu, and the join date as June 2010. The profile also shows 571 photos and videos. The tweet feed includes a pinned tweet from October 24 about Commissioner Moedas getting an Ebola vaccine trial experience with an iris scan, and a recent tweet from 38 minutes ago about the next week's BIOEUROPE event in Berlin.

Your contact points

At the IMI Programme Office

- General queries: applicants@imi.europa.eu
- IP queries: IMI-IP-Helpdesk@imi.europa.eu

Local contacts

- IMI2 JU States Representatives Group: bit.ly/IMISRG
- Horizon 2020 Health National Contact Points: bit.ly/H2020_NCPs



Thank you



Questions

Questions?

Raise your hand
if you want to ask a
question orally



Send a question in writing



After the webinar, send any questions
to the **IMI Programme Office**

applicants@imi.europa.eu

The screenshot shows the GoToWebinar interface. At the top, there is a menu with 'File', 'View', and 'Help'. Below the menu is the 'Audio' panel, which includes a 'Sound Check' indicator and two radio buttons: 'Computer audio' (selected) and 'Phone call'. A microphone icon is shown with the word 'MUTED' in orange. Below this, there are dropdown menus for 'Transmit (Plantronics Savi 7xx-M)' and 'Receive (Plantronics Savi 7xx-M)'. A volume bar is also visible. Below the audio panel is the 'Questions' panel, which contains a text input field with the placeholder '[Enter a question for staff]' and a 'Send' button. At the bottom of the interface, there is a 'Webinar Housekeeping' section with the text 'Webinar ID: 608-865-371' and the GoToWebinar logo.